1. Janux Therapeutics, Inc. (NASDAQ:JANX)
Number of Hedge Fund Holders as of Q4: 54
Adage Capital Management’s Equity Stake: $163.93 Million
Upside Potential as of May 2: 189.86%
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immunotherapies designed to generate tumor-specific immune responses. The company focuses on therapies that target and destroy cancer cells while sparing healthy tissue, thereby minimizing adverse effects often associated with traditional cancer treatments.
Financially, Janux Therapeutics, Inc. (NASDAQ:JANX) demonstrated a robust capital position at the close of 2024. As of December 31, the company reported $1.03 billion in cash, cash equivalents, and short-term investments, a substantial increase from $344.0 million reported at the end of 2023. This significant boost in financial reserves positions Janux to sustain and accelerate its research efforts over the coming years. The company’s research and development expenses rose to $20.8 million for the fourth quarter and totalled $68.4 million for the year, compared to $12.2 million and $54.9 million for the same periods in 2023, reflecting intensified clinical activity and investment in its pipeline. Likewise, general and administrative expenses grew to $8.2 million for the quarter and $41.0 million for the full year, up from $6.4 million and $26.1 million in the prior year, as the company expanded its operational infrastructure to support clinical development and long-term growth.
Despite increased expenditures, Janux Therapeutics, Inc. (NASDAQ:JANX) reported a net loss of $20.2 million for the fourth quarter and $69.0 million for the full year of 2024, compared to $11.8 million and $58.3 million in 2023. These figures are consistent with a company in the clinical development phase, where investments in research, trials, and infrastructure precede revenue generation. The increased losses correspond with the company’s strategic ramp-up of its therapeutic programs and development pipeline. Janux remains well-capitalized and committed to advancing its mission of delivering transformative immunotherapies that leverage tumor-specific biology to safely and effectively combat cancer.
In the fourth quarter of 2024, Adage Capital Management significantly increased its investment in Janux Therapeutics, Inc. (NASDAQ:JANX), increasing its position to over 3 million shares—a 48% rise from the 2.08 million shares held in the previous quarter. This expansion brought the fund’s total stake in the company to an estimated $1.6 billion.
Overall, JANX ranks first among unknown billionaire Phill Gross’ 10 stock picks with huge upside potential. While we acknowledge the potential of these stock picks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than JANX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stock To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
